Theravance Biopharma
TBPH • NASDAQ
Theravance Biopharma is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Rick E. Winningham, with a market cap of $776.5M.
CEORick E. Winningham
Next Earnings
Upcoming earnings announcement for Theravance Biopharma
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.07
Revenue Estimate
$19.8M
Earnings History
Past 12 earnings reports for Theravance Biopharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 19, 2026 | Q4 2025 | $1.15Est: $0.34 | +238.2% | $45.9MEst: $54.3M | -15.6% |  10-K |
| Nov 10, 2025 | Q3 2025 | $0.07Est: -$0.08 | +187.5% | $20.0MEst: $19.8M | +1.1% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.08Est: -$0.17 | +52.9% | $26.2MEst: $22.4M | +16.7% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.27Est: -$0.09 | -200.0% | $15.4MEst: $28.1M | -45.2% | 10-Q |
| Feb 26, 2025 | Q4 2024 | -$0.05Est: -$0.08 | +37.5% | $18.8MEst: $17.1M | +9.7% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.06Est: -$0.23 | +73.9% | $16.9MEst: $15.3M | +10.0% | 10-Q |
| Aug 5, 2024 | Q2 2024 | -$0.13Est: -$0.21 | +38.1% | $14.3MEst: $15.5M | -7.7% | 10-Q |
| May 13, 2024 | Q1 2024 | -$0.09Est: -$0.25 | +64.0% | $14.5MEst: $14.0M | +3.9% | 10-Q |
| Feb 26, 2024 | Q4 2023 | -$0.17Est: -$0.15 | -13.3% | $17.6MEst: $17.7M | -0.7% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.17Est: -$0.21 | +19.0% | $15.7MEst: $15.0M | +4.6% | — |
| Aug 7, 2023 | Q2 2023 | -$0.13Est: -$0.16 | +18.8% | $13.7MEst: $15.2M | -9.8% | 10-Q |
| May 8, 2023 | Q1 2023 | -$0.24Est: -$0.26 | +7.7% | $10.4MEst: $13.8M | -24.7% | — |